RENO, Nev., June 28, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (PINKSHEETS: LLBO) announces the USPTO has awarded US Patent #8,185,485 B2 for a Device for Analyzing Thermal Data Based on Breast Surface Temperature for the Detection for use in Determining Cancerous Conditions.
"This has taken considerable effort to reach the conclusion of a milestone that started with our clinical trials and a patent filing August 27, 2008. We knew our core science charted new territory and was unique because it took considerable resources to achieve our results," says Jim Holmes, Chairman/CEO.
"The foundation of this Company is our two issued patents (developed data collection device and the software patent above referenced) together with two pending patents (a software patent and a methods patent). Based on this intellectual property, we are supporting our licensee, First Warning Systems, Inc. in moving ahead with investment and commercialization plans," adds Holmes.
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancers. Two patents are awarded, two patents are pending; three clinical trials with over 650 participants have been completed. Proof of Concept has been confirmed. www.lbti.com
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
For more information, contact:
Jim Holmes, CEO P: 775-324-1933 E: email@example.com
|SOURCE Lifeline Biotechnologies, Inc.|
Copyright©2012 PR Newswire.
All rights reserved